ClinicalTrials.gg

Program

QLS4131

A development code. Also written as “QLS4131 for Injection.” and “QLS4131 Injection”.

Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic, led by Qilu Pharmaceutical.

Furthest: phase 3, since Nov 6, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical33 open or runningphase 3since Nov 6, 2026Jul 8, 2024Dec 2026phase 1 · NCT07001839

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2024First study: phase 1 study in RecurrenceFirst studyNCT06500507 · 90 planned · China
  2. May 25, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07001839 · 108 planned
  3. Nov 6, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07933432 · 300 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07001839
  2. Dec 14, 2029Primary completion: phase 3 study in RecurrenceNCT07933432

TargetBeta

CD3E →GPRC5D →read by rule
“The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL).”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 37
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS32015ruleQilu Pharmaceuticalphase 32
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933432Recurrence3Not yet recruitingDec 14, 2029300
NCT07001839Lupus Erythematosus, Systemic1Not yet recruitingDec 2026108
NCT06500507Recurrence · China1Not yet recruitingMar 31, 202690

How it is read

Names in the registry

  • “QLS4131”, 1 entry
  • “QLS4131 for Injection.”, 1 entry
  • “QLS4131 Injection”, 1 entry

Codes read as this program: QLS4131.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.